Clear Cell Ovarian Carcinoma Following Long-Term Tamoxifen Use

Jennings TS, T. Scott Jennings, Haddad ME, Mary Haddad, Mary E. Haddad, Timothy M. Smith, Smith TM
The breast journal · 1999 · vol. 5(2) , pp. 132–135 · doi:10.1046/j.1524-4741.1999.00137.x · PMID:11348273 · W1991695890
Case report OA: closed CC0 ⤵ 3 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-29 ⓘ

This report details a case of clear cell ovarian cancer and endometriosis in a postmenopausal patient with a history of tamoxifen use for breast cancer, noting progesterone receptor positivity in the tumor.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A case of clear cell ovarian cancer and endometriosis in a postmenopausal patient following adjuvant tamoxifen for breast cancer is presented. Immunohistochemistry demonstrated the tumor to be positive for progesterone receptor protein but not estrogen receptor protein; the endometriosis was positive for both proteins. Literature review reveals this to be the first report of both clear cell ovarian cancer and endometriosis following tamoxifen use, and the third report of epithelial ovarian cancer associated with tamoxifen.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Cited by (3)

Source provenance

europepmc
last seen: 2026-10-26T06:15:05.866214+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T20:59:53.382863+00:00
unpaywall
last seen: 2026-09-03T06:36:50.994332+00:00
License: CC0 · commercial use OK